Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30


Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs.

Tricot L, Teicher E, Peytavin G, Zucman D, Conti F, Calmus Y, Barrou B, Duvivier C, Fontaine C, Welker Y, Billy C, de Truchis P, Delahousse M, Vittecoq D, Salmon-Céron D.

Am J Transplant. 2009 Aug;9(8):1946-52. doi: 10.1111/j.1600-6143.2009.02684.x.


Prevalence and clinical characteristics of HIV type 1-infected patients receiving dialysis in Spain: results of a Spanish survey in 2006: GESIDA 48/05 study.

Trullàs JC, Barril G, Cofan F, Moreno A, Cases A, Fernandez-Lucas M, Martinez-Ara J, Ceballos M, Garcia-de-Diego J, Muñiz ML, Molina J, Martínez-Castelao A, González-Garcia J, Miró JM; Spanish HIV Infection in Dialysis Study Group..

AIDS Res Hum Retroviruses. 2008 Oct;24(10):1229-35. doi: 10.1089/aid.2008.0158.


Renal disease in patients with HIV infection: epidemiology, pathogenesis and management.

Fine DM, Perazella MA, Lucas GM, Atta MG.

Drugs. 2008;68(7):963-80. Review.


Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease.

Choi AI, Rodriguez RA, Bacchetti P, Volberding PA, Havlir D, Bertenthal D, Bostrom A, O'Hare AM.

Clin Infect Dis. 2007 Dec 15;45(12):1633-9. doi: 10.1086/523729.


Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients.

Frassetto LA, Browne M, Cheng A, Wolfe AR, Roland ME, Stock PG, Carlson L, Benet LZ.

Am J Transplant. 2007 Dec;7(12):2816-20.


Malignancy after kidney transplantation: still a challenge.

Bosmans JL, Verpooten GA.

Kidney Int. 2007 Jun;71(12):1197-9.


Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity.

Selin LK, Brehm MA, Naumov YN, Cornberg M, Kim SK, Clute SC, Welsh RM.

Immunol Rev. 2006 Jun;211:164-81. Review.


Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation.

Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila-Pico C, Machicao VI, Cabrera R, Reed AI, Liu C, Nelson DR.

Liver Transpl. 2006 Jan;12(1):51-7.


Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients.

Frassetto L, Baluom M, Jacobsen W, Christians U, Roland ME, Stock PG, Carlson L, Benet LZ.

Transplantation. 2005 Jul 15;80(1):13-7.


Sirolimus for Kaposi's sarcoma in renal-transplant recipients.

Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G.

N Engl J Med. 2005 Mar 31;352(13):1317-23.


Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects.

Frassetto L, Thai T, Aggarwal AM, Bucher P, Jacobsen W, Christians U, Benet LZ, Floren LC.

Drug Metab Pharmacokinet. 2003;18(2):114-20.


Homeostatic proliferation is a barrier to transplantation tolerance.

Wu Z, Bensinger SJ, Zhang J, Chen C, Yuan X, Huang X, Markmann JF, Kassaee A, Rosengard BR, Hancock WW, Sayegh MH, Turka LA.

Nat Med. 2004 Jan;10(1):87-92.


Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.

Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K.

Hepatology. 2003 Nov;38(5):1282-8.


Heterologous immunity provides a potent barrier to transplantation tolerance.

Adams AB, Williams MA, Jones TR, Shirasugi N, Durham MM, Kaech SM, Wherry EJ, Onami T, Lanier JG, Kokko KE, Pearson TC, Ahmed R, Larsen CP.

J Clin Invest. 2003 Jun;111(12):1887-95.


Direct visualization of cross-reactive effector and memory allo-specific CD8 T cells generated in response to viral infections.

Brehm MA, Markees TG, Daniels KA, Greiner DL, Rossini AA, Welsh RM.

J Immunol. 2003 Apr 15;170(8):4077-86.


Recent progress in HIV-associated nephropathy.

Ross MJ, Klotman PE.

J Am Soc Nephrol. 2002 Dec;13(12):2997-3004. Review. No abstract available.


Cutting edge: persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen.

Williams MA, Onami TM, Adams AB, Durham MM, Pearson TC, Ahmed R, Larsen CP.

J Immunol. 2002 Nov 15;169(10):5387-91.


Characterization of virus-mediated inhibition of mixed chimerism and allospecific tolerance.

Williams MA, Tan JT, Adams AB, Durham MM, Shirasugi N, Whitmire JK, Harrington LE, Ahmed R, Pearson TC, Larsen CP.

J Immunol. 2001 Nov 1;167(9):4987-95.


HIV-associated nephropathy: an urban epidemic.

Monahan M, Tanji N, Klotman PE.

Semin Nephrol. 2001 Jul;21(4):394-402. Review.

Items per page

Supplemental Content

Support Center